Reanalysis of the ESPS 2 trial – Efficacy among high-risk subgroups
Relative Hazard Reductions for DP + ASA vs. ASA
Among High-risk Subgroups Using Framingham Model
References
Sacco et al. Arch Neurol 2005; 62 (3): 403-408.
PubMed Abstract
